This poster presents Ncardia’s platform for generating non-human primate (NHP) iPSC-derived ventricular cardiomyocytes, designed to support translational cardiac safety assessment alongside human iPSC-based models.
By enabling controlled comparison between NHP and human cardiomyocytes, the system provides new insight into species-specific pharmacology and cardiac safety signals during early drug development.
Download it now for a closer look at:
Scalable differentiation of cynomolgus macaque iPSCs into ventricular cardiomyocytes using stirred tank bioreactors
Structural and functional characterization using immunostaining, MEA electrophysiology, and impedance-based contractility assays
Comparative pharmacology between NHP cardiomyocytes and human Ncyte® vCardiomyocytes, revealing species-specific responses to cardioactive compounds
Detection of distinct arrhythmia and chronic toxicity signatures, supporting improved translation between in vitro and in vivo safety studies
Could non-human primate iPSC-derived cardiomyocytes help bridge the gap between human in vitro models and in vivo safety studies in your program?